{"disease":{"id":"cin","name":"cin"},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Transitional cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"nivolumab","indication_name":"Squamous cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"nivolumab","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"nivolumab","indication_name":"Postoperative adjuvant therapy for urothelial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"durvalumab","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imfinzi","generic_name":"durvalumab","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":"4900","mechanism":"Imfinzi works by blocking the PD-L1 protein, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"durvalumab","indication_name":"Metastatic carcinoma to biliary tract","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imfinzi","generic_name":"durvalumab","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":"4900","mechanism":"Imfinzi works by blocking the PD-L1 protein, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"durvalumab","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imfinzi","generic_name":"durvalumab","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":"4900","mechanism":"Imfinzi works by blocking the PD-L1 protein, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"durvalumab","indication_name":"Transitional cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imfinzi","generic_name":"durvalumab","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":"4900","mechanism":"Imfinzi works by blocking the PD-L1 protein, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"durvalumab","indication_name":"Extensive stage primary small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imfinzi","generic_name":"durvalumab","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":"4900","mechanism":"Imfinzi works by blocking the PD-L1 protein, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"ibrance","indication_name":"Human epidermal growth factor 2 negative carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ibrance","generic_name":"Palbociclib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":88,"revenue":"4500","mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"atezolizumab","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tecentriq","generic_name":"atezolizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"3700","mechanism":"Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system."},{"drug_id":"abemaciclib","indication_name":"Human epidermal growth factor 2 negative carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Verzenio","generic_name":"abemaciclib","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/CDK6)","drug_class":"Kinase inhibitor","quality_score":78,"revenue":"3700","mechanism":"Abemaciclib inhibits CDK4 and CDK6, blocking Rb phosphorylation and G1/S cell cycle progression."},{"drug_id":"atezolizumab","indication_name":"Extensive stage primary small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tecentriq","generic_name":"atezolizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"3700","mechanism":"Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system."},{"drug_id":"atezolizumab","indication_name":"Transitional cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tecentriq","generic_name":"atezolizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"3700","mechanism":"Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system."},{"drug_id":"trastuzumab-deruxtecan","indication_name":"Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enhertu","generic_name":"trastuzumab-deruxtecan","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":63,"revenue":"2900","mechanism":"Enhertu works by binding to the HER2 protein and releasing a cytotoxic payload to kill cancer cells."},{"drug_id":"trastuzumab-deruxtecan","indication_name":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enhertu","generic_name":"trastuzumab-deruxtecan","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":63,"revenue":"2900","mechanism":"Enhertu works by binding to the HER2 protein and releasing a cytotoxic payload to kill cancer cells."},{"drug_id":"trastuzumab","indication_name":"HER2-positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Herceptin","generic_name":"trastuzumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"HER2 receptor, subdomain IV","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"2900","mechanism":"HER2-targeted antibody-drug conjugate delivering microtubule inhibitor DM1 to HER2-overexpressing cells."},{"drug_id":"ipilimumab","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yervoy","generic_name":"ipilimumab","company_name":"Bristol-Myers Squibb","drug_phase":"discontinued","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody","quality_score":0,"revenue":"2900","mechanism":"Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells."},{"drug_id":"olaparib","indication_name":"Human epidermal growth factor 2 negative carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lynparza","generic_name":"olaparib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 2","drug_class":"Poly(ADP-Ribose) Polymerase Inhibitor [EPC]","quality_score":73,"revenue":"2600","mechanism":"Lynparza blocks the repair of DNA damage in cancer cells by inhibiting the enzyme PARP."},{"drug_id":"ags-22m6e","indication_name":"Metastatic urothelial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Padcev","generic_name":"AGS-22M6E","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Nectin-4","drug_class":"","quality_score":70,"revenue":"2300","mechanism":"Padcev works by binding to Nectin-4 on the surface of cancer cells, marking them for destruction."},{"drug_id":"cabometyx","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"Cabometyx","company_name":"Exelixis","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":70,"revenue":"2200","mechanism":"Cometriq blocks the VEGFR2 pathway to prevent tumor growth and angiogenesis."},{"drug_id":"cabometyx","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"Cabometyx","company_name":"Exelixis","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":70,"revenue":"2200","mechanism":"Cometriq blocks the VEGFR2 pathway to prevent tumor growth and angiogenesis."},{"drug_id":"cabometyx","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"Cabometyx","company_name":"Exelixis","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":70,"revenue":"2200","mechanism":"Cometriq blocks the VEGFR2 pathway to prevent tumor growth and angiogenesis."},{"drug_id":"cabometyx","indication_name":"Medullary thyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"Cabometyx","company_name":"Exelixis","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":70,"revenue":"2200","mechanism":"Cometriq blocks the VEGFR2 pathway to prevent tumor growth and angiogenesis."},{"drug_id":"bevacizumab","indication_name":"Metastatic carcinoma to colon","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avastin","generic_name":"bevacizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":82,"revenue":"2100","mechanism":"Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors."},{"drug_id":"bevacizumab","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avastin","generic_name":"bevacizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":82,"revenue":"2100","mechanism":"Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors."},{"drug_id":"bevacizumab","indication_name":"Carcinoma of cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avastin","generic_name":"bevacizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":82,"revenue":"2100","mechanism":"Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors."},{"drug_id":"bevacizumab","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avastin","generic_name":"bevacizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":82,"revenue":"2100","mechanism":"Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors."},{"drug_id":"cemiplimab","indication_name":"Metastatic basal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Libtayo","generic_name":"CEMIPLIMAB","company_name":"Regeneron Pharmaceuticals ","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"","quality_score":64,"revenue":"1452","mechanism":"Cemiplimab-rwlc binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors."},{"drug_id":"cemiplimab","indication_name":"Squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Libtayo","generic_name":"CEMIPLIMAB","company_name":"Regeneron Pharmaceuticals ","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"","quality_score":64,"revenue":"1452","mechanism":"Cemiplimab-rwlc binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors."},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Head and Neck Squamous Cell Carcinoma (HNSCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Urothelial Carcinoma (UC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"lanreotide","indication_name":"Carcinoid Syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Somatuline Depot","generic_name":"LANREOTIDE","company_name":"Ipsen Pharma","drug_phase":"marketed","molecular_target":"Somatostatin receptor type 2","drug_class":"Somatostatin Analog","quality_score":10,"revenue":"1200","mechanism":"Somatuline Depot works by mimicking the natural hormone somatostatin to block the production of excess growth hormone."},{"drug_id":"lenvatinib","indication_name":"Papillary thyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lenvima","generic_name":"LENVATINIB","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":"1053.0","mechanism":"Lenvima works by blocking the activity of a specific protein called Ret, which is involved in the growth and spread of cancer cells."},{"drug_id":"lenvatinib","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lenvima","generic_name":"LENVATINIB","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":"1053.0","mechanism":"Lenvima works by blocking the activity of a specific protein called Ret, which is involved in the growth and spread of cancer cells."},{"drug_id":"lenvatinib","indication_name":"Hurthle cell carcinoma of thyroid","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lenvima","generic_name":"LENVATINIB","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":"1053.0","mechanism":"Lenvima works by blocking the activity of a specific protein called Ret, which is involved in the growth and spread of cancer cells."},{"drug_id":"lenvatinib","indication_name":"Follicular thyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lenvima","generic_name":"LENVATINIB","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":"1053.0","mechanism":"Lenvima works by blocking the activity of a specific protein called Ret, which is involved in the growth and spread of cancer cells."},{"drug_id":"lenvatinib","indication_name":"Endometrial carcinoma progressing after chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lenvima","generic_name":"LENVATINIB","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":"1053.0","mechanism":"Lenvima works by blocking the activity of a specific protein called Ret, which is involved in the growth and spread of cancer cells."},{"drug_id":"lenvatinib","indication_name":"Thymic carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lenvima","generic_name":"LENVATINIB","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":"1053.0","mechanism":"Lenvima works by blocking the activity of a specific protein called Ret, which is involved in the growth and spread of cancer cells."},{"drug_id":"lenvatinib","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lenvima","generic_name":"LENVATINIB","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":"1053.0","mechanism":"Lenvima works by blocking the activity of a specific protein called Ret, which is involved in the growth and spread of cancer cells."},{"drug_id":"abrysvo","indication_name":"Prevention of rabies in individuals who have been bitten or otherwise exposed to rabies or have been at risk of rabies exposure and have been vaccinated with a cell culture vaccine or an inactivated rabies vaccine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrysvo","generic_name":"abrysvo","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"RSV","drug_class":"vaccine","quality_score":60,"revenue":"1033","mechanism":"ABRYSVO is a vaccine that protects against respiratory syncytial virus (RSV)."},{"drug_id":"cyclophosphamide","indication_name":"Adenocarcinoma of the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"cyclophosphamide","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"axitinib","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inlyta","generic_name":"axitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mast/stem cell growth factor receptor Kit","drug_class":"Kinase Inhibitor [EPC]","quality_score":82,"revenue":"923","mechanism":"Inlyta works by blocking the activity of the mast/stem cell growth factor receptor Kit, which is involved in the growth and spread of cancer cells."},{"drug_id":"tislelizumab","indication_name":"Unresectable or metastatic esophageal squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tevimbra","generic_name":"TISLELIZUMAB","company_name":"Beigene","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"900","mechanism":"Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"ramucirumab","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyramza","generic_name":"RAMUCIRUMAB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]","quality_score":10,"revenue":"900","mechanism":"Cyramza blocks the VEGFR2 receptor, which is involved in cancer cell growth and spread."},{"drug_id":"ramucirumab","indication_name":"Adenocarcinoma of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyramza","generic_name":"RAMUCIRUMAB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]","quality_score":10,"revenue":"900","mechanism":"Cyramza blocks the VEGFR2 receptor, which is involved in cancer cell growth and spread."},{"drug_id":"tislelizumab","indication_name":"Unresectable or metastatic esophageal squamous cell carcinoma (ESCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tevimbra","generic_name":"TISLELIZUMAB","company_name":"Beigene","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"900","mechanism":"Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"tislelizumab","indication_name":"Unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tevimbra","generic_name":"TISLELIZUMAB","company_name":"Beigene","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"900","mechanism":"Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"tislelizumab","indication_name":"Gastric or gastroesophageal junction adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tevimbra","generic_name":"TISLELIZUMAB","company_name":"Beigene","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"900","mechanism":"Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"tislelizumab","indication_name":"Esophageal Squamous Cell Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tevimbra","generic_name":"TISLELIZUMAB","company_name":"Beigene","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"900","mechanism":"Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"selpercatinib","indication_name":"Medullary thyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retevmo","generic_name":"SELPERCATINIB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":69,"revenue":"700","mechanism":"Retevmo works by blocking the activity of the RET protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"everolimus","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Afinitor","generic_name":"everolimus","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"600","mechanism":"Afinitor works by blocking the mTOR protein, which is involved in cell growth and division."},{"drug_id":"everolimus","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Afinitor","generic_name":"everolimus","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"600","mechanism":"Afinitor works by blocking the mTOR protein, which is involved in cell growth and division."},{"drug_id":"niraparib","indication_name":"Carcinoma in situ of fallopian tube","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zejula","generic_name":"niraparib","company_name":"GSK","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 2","drug_class":"Poly(ADP-Ribose) Polymerase Inhibitor","quality_score":69,"revenue":"600","mechanism":"Zejula works by blocking the action of an enzyme called PARP, which helps repair damaged DNA in cancer cells."},{"drug_id":"belzutifan","indication_name":"Advanced Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Welireg","generic_name":"BELZUTIFAN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"HIF-2α","drug_class":"Hypoxia-inducible Factor Inhibitor [EPC]","quality_score":75,"revenue":"509","mechanism":"Belzutifan inhibits HIF-2α, blocking its interaction with HIF-1β to reduce expression of genes linked to tumor growth."},{"drug_id":"tukysa","indication_name":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tukysa","generic_name":"tukysa","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ERBB2/ERBB3","drug_class":"Kinase Inhibitor [EPC]","quality_score":65,"revenue":"463","mechanism":"Tukysa blocks the activity of ERBB2 and ERBB3 proteins, which are involved in cancer cell growth and spread."},{"drug_id":"tucatinib","indication_name":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tukysa","generic_name":"tucatinib","company_name":"Seagen","drug_phase":"marketed","molecular_target":"ERBB2/ERBB3","drug_class":"Kinase Inhibitor [EPC]","quality_score":59,"revenue":"463","mechanism":"Tukysa works by blocking the ERBB2/ERBB3 receptors, which are involved in the growth and spread of cancer cells."},{"drug_id":"tremelimumab","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imjudo","generic_name":"TREMELIMUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"CTLA-4","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":62,"revenue":"400","mechanism":"Tremelimumab-actl binds to CTLA-4, blocking its interaction with CD80 and CD86, thereby enhancing T-cell activation and reducing tumor growth."},{"drug_id":"avelumab","indication_name":"Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bavencio","generic_name":"avelumab","company_name":"Merck KGaA","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":69,"revenue":"400","mechanism":"Bavencio blocks the PD-L1 protein, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"avelumab","indication_name":"Merkel cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bavencio","generic_name":"avelumab","company_name":"Merck KGaA","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":69,"revenue":"400","mechanism":"Bavencio blocks the PD-L1 protein, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"regorafenib","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Stivarga","generic_name":"regorafenib","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Bifunctional epoxide hydrolase 2","drug_class":"Kinase Inhibitor","quality_score":86,"revenue":"400","mechanism":"Stivarga blocks the activity of enzymes involved in tumor growth and angiogenesis."},{"drug_id":"eribulin","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Halaven","generic_name":"ERIBULIN","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Tubulin beta","drug_class":"Microtubule Inhibitor","quality_score":71,"revenue":"400","mechanism":"Halaven works by binding to tubulin beta, disrupting microtubule dynamics and leading to cell death."},{"drug_id":"avelumab","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bavencio","generic_name":"avelumab","company_name":"Merck KGaA","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":69,"revenue":"400","mechanism":"Bavencio blocks the PD-L1 protein, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"nabpaclitaxel","indication_name":"Carcinoma of fallopian tube","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"Nabpaclitaxel","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":null,"revenue":"368","mechanism":"Taxol works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division."},{"drug_id":"nabpaclitaxel","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"Nabpaclitaxel","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":null,"revenue":"368","mechanism":"Taxol works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division."},{"drug_id":"nabpaclitaxel","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"Nabpaclitaxel","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":null,"revenue":"368","mechanism":"Taxol works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division."},{"drug_id":"paclitaxel","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor [EPC]","quality_score":76,"revenue":"368","mechanism":""},{"drug_id":"paclitaxel","indication_name":"Carcinoma of fallopian tube","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor [EPC]","quality_score":76,"revenue":"368","mechanism":""},{"drug_id":"paclitaxel","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor [EPC]","quality_score":76,"revenue":"368","mechanism":""},{"drug_id":"nab-paclitaxel","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"nab-paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":57,"revenue":"368","mechanism":""},{"drug_id":"nab-paclitaxel","indication_name":"Carcinoma of fallopian tube","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"nab-paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":57,"revenue":"368","mechanism":""},{"drug_id":"nab-paclitaxel","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"nab-paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":57,"revenue":"368","mechanism":""},{"drug_id":"octreotide","indication_name":"Carcinoid syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sandostatin","generic_name":"OCTREOTIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Somatostatin receptor type 2","drug_class":"Somatostatin Analog","quality_score":75,"revenue":"305","mechanism":"Sandostatin works by mimicking the natural hormone somatostatin to inhibit the release of various hormones and growth factors."},{"drug_id":"erdafitinib","indication_name":"Locally advanced or metastatic urothelial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Balversa","generic_name":"ERDAFITINIB","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Fibroblast growth factor receptor 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":65,"revenue":"300","mechanism":"Balversa works by blocking the fibroblast growth factor receptor 1, a protein that helps cancer cells grow and spread."},{"drug_id":"jevtana","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Jevtana","company_name":"Bayer","drug_phase":"discontinued","molecular_target":"Tubulin beta","drug_class":"","quality_score":null,"revenue":"300","mechanism":""},{"drug_id":"erdafitinib","indication_name":"Metastatic urothelial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Balversa","generic_name":"ERDAFITINIB","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Fibroblast growth factor receptor 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":65,"revenue":"300","mechanism":"Balversa works by blocking the fibroblast growth factor receptor 1, a protein that helps cancer cells grow and spread."},{"drug_id":"cabazitaxel","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jevtana Kit","generic_name":"cabazitaxel","company_name":"Accord Hlthcare","drug_phase":"marketed","molecular_target":"Tubulin beta","drug_class":"Microtubule Inhibitor","quality_score":80,"revenue":"300","mechanism":"Cabazitaxel works by binding to tubulin beta, disrupting microtubule formation and preventing cancer cell division."},{"drug_id":"balversa","indication_name":"Metastatic urothelial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Balversa","company_name":"xCures","drug_phase":"discontinued","molecular_target":"Fibroblast growth factor receptor 1, Fibroblast growth factor receptor 2, Fibroblast growth factor receptor 3","drug_class":"","quality_score":null,"revenue":"300","mechanism":""},{"drug_id":"pemigatinib","indication_name":"Malignant neoplasm of common bile duct (& [carcinoma])","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pemazyre","generic_name":"PEMIGATINIB","company_name":"Incyte Corp","drug_phase":"marketed","molecular_target":"Fibroblast growth factor receptor 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":"200","mechanism":"Pemazyre blocks the activity of the FGFR1 protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"sorafenib","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nexavar","generic_name":"SORAFENIB","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor [EPC]","quality_score":65,"revenue":"200","mechanism":""},{"drug_id":"sorafenib","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nexavar","generic_name":"SORAFENIB","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor [EPC]","quality_score":65,"revenue":"200","mechanism":""},{"drug_id":"sorafenib","indication_name":"Carcinoma of thyroid","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nexavar","generic_name":"SORAFENIB","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor [EPC]","quality_score":65,"revenue":"200","mechanism":""},{"drug_id":"zolbetuximab","indication_name":"locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyloy","generic_name":"ZOLBETUXIMAB","company_name":"Astellas","drug_phase":"marketed","molecular_target":"","drug_class":"Claudin 18.2-directed Cytolytic Antibody [EPC]","quality_score":55,"revenue":"100","mechanism":"Vyloy works by binding to Claudin 18.2 on cancer cells, triggering their destruction."},{"drug_id":"zolbetuximab","indication_name":"locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyloy","generic_name":"ZOLBETUXIMAB","company_name":"Astellas","drug_phase":"marketed","molecular_target":"","drug_class":"Claudin 18.2-directed Cytolytic Antibody [EPC]","quality_score":55,"revenue":"100","mechanism":"Vyloy works by binding to Claudin 18.2 on cancer cells, triggering their destruction."},{"drug_id":"temsirolimus","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Torisel","generic_name":"temsirolimus","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"Kinase Inhibitor","quality_score":60,"revenue":null,"mechanism":"Torisel works by blocking the mTOR protein, which is involved in cell growth and division."},{"drug_id":"toripalimab","indication_name":"metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Loqtorzi","generic_name":"TORIPALIMAB","company_name":"Coherus Biosciences Inc","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Loqtorzi blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"nilutamide","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nilandron","generic_name":"NILUTAMIDE","company_name":"Advanz","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen Receptor Inhibitor [EPC]","quality_score":52,"revenue":null,"mechanism":""},{"drug_id":"sulbactam","indication_name":"Hospital-acquired bacterial pneumonia caused by acinetobacter baumannii-calcoaceticus complex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"SULBACTAM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine beta-lactamase-like protein LACTB, mitochondrial","drug_class":"beta Lactamase Inhibitor","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"sulbactam","indication_name":"Infection caused by carbapenem-resistant acinetobacter baumannii-calcoaceticus complex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"SULBACTAM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine beta-lactamase-like protein LACTB, mitochondrial","drug_class":"beta Lactamase Inhibitor","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"sulbactam","indication_name":"Skin and Skin Structure Acinetobacter Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"SULBACTAM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine beta-lactamase-like protein LACTB, mitochondrial","drug_class":"beta Lactamase Inhibitor","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"sulbactam","indication_name":"Ventilator-associated bacterial pneumonia caused by acinetobacter baumannii-calcoaceticus complex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"SULBACTAM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine beta-lactamase-like protein LACTB, mitochondrial","drug_class":"beta Lactamase Inhibitor","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"cisplatin","indication_name":"Ovarian Germ Cell Tumor Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Platinol-Aq","generic_name":"cisplatin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Platinum-based Drug [EPC]","quality_score":52,"revenue":null,"mechanism":""},{"drug_id":"leuprolide","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lupron","generic_name":"leuprolide","company_name":"Accord Healthcare S.L.U.","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"Gonadotropin Releasing Hormone Receptor Agonist","quality_score":75,"revenue":null,"mechanism":"Lupron works by binding to and activating the gonadotropin-releasing hormone receptor, which ultimately leads to a decrease in the production of sex hormones."},{"drug_id":"cinacalcet","indication_name":"Parathyroid Carcinoma with Hypercalcemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sensipar","generic_name":"CINACALCET","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Extracellular calcium-sensing receptor","drug_class":"Calcium-sensing Receptor Agonist","quality_score":65,"revenue":null,"mechanism":"Sensipar works by activating the calcium-sensing receptor, which helps regulate calcium levels in the blood."},{"drug_id":"margetuximab","indication_name":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Margenza","generic_name":"MARGETUXIMAB","company_name":"Macrogenics Inc","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"HER2/neu Receptor Antagonist [EPC]","quality_score":55,"revenue":null,"mechanism":"Margenza works by blocking the HER2/neu receptor, which is overexpressed in certain breast cancer cells, to prevent them from growing and multiplying."},{"drug_id":"penpulimab","indication_name":"Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Penpulimab kcqx","generic_name":"PENPULIMAB","company_name":"Akeso Biopharma","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Penpulimab works by binding to the PD-1 protein on immune cells, blocking its interaction with the PD-L1 protein on cancer cells and allowing the immune system to attack the cancer."},{"drug_id":"penpulimab","indication_name":"Metastatic Non-Keratinizing Nasopharyngeal Carcinoma with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Penpulimab kcqx","generic_name":"PENPULIMAB","company_name":"Akeso Biopharma","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Penpulimab works by binding to the PD-1 protein on immune cells, blocking its interaction with the PD-L1 protein on cancer cells and allowing the immune system to attack the cancer."},{"drug_id":"epirubicin","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ellence","generic_name":"EPIRUBICIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Fyn","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":62,"revenue":null,"mechanism":"Ellence works by intercalating DNA and inhibiting topoisomerase II, disrupting cancer cell growth."},{"drug_id":"zirabev","indication_name":"Carcinoma of cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab","generic_name":"Bevacizumab-Bvzr","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular Endothelial Growth Factor (VEGF)","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR."},{"drug_id":"zirabev","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab","generic_name":"Bevacizumab-Bvzr","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular Endothelial Growth Factor (VEGF)","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR."},{"drug_id":"zirabev","indication_name":"Metastatic carcinoma to colon","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab","generic_name":"Bevacizumab-Bvzr","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular Endothelial Growth Factor (VEGF)","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR."},{"drug_id":"zirabev","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab","generic_name":"Bevacizumab-Bvzr","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular Endothelial Growth Factor (VEGF)","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR."},{"drug_id":"inositol-nicotinate","indication_name":"Niacin deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hexanicit","generic_name":"inositol nicotinate","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"inositol nicotinate","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"mitomycin","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mitozytrex","generic_name":"MITOMYCIN","company_name":"Kyowa Kirin Co., Ltd.","drug_phase":"marketed","molecular_target":"Indoleamine 2,3-dioxygenase 1","drug_class":"Alkylating Drug [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"piperacillin","indication_name":"Skin and Skin Structure Acinetobacter Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pipracil","generic_name":"PIPERACILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"piperacillin","quality_score":10,"revenue":null,"mechanism":"Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death."},{"drug_id":"bavencio","indication_name":"Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bavencio","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"bavencio","indication_name":"Merkel cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bavencio","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"bavencio","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bavencio","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"casodex","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Casodex","company_name":"University Health Network, Toronto","drug_phase":"discontinued","molecular_target":"Cytochrome P450 2C19, Androgen receptor, Androgen receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"raloxifene","indication_name":"Prevention of Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Evista","generic_name":"RALOXIFENE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"estrogen receptors","drug_class":"Estrogen Agonist/Antagonist","quality_score":75,"revenue":null,"mechanism":"Raloxifene binds to estrogen receptors, acting as an agonist in bone and an antagonist in uterine and breast tissues."},{"drug_id":"flu-vaccine","indication_name":"Prevention of influenza caused by virus subtypes A and B contained in the vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flu Vaccine","company_name":"La Fundacion Favaloro para la Investigacion y la Docencia Medica","drug_phase":"marketed","molecular_target":"Influenza A and B viral hemagglutinin and neuraminidase surface antigens","drug_class":"Prophylactic vaccine","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"lopid","indication_name":"Reducing risk of developing coronary heart disease in Type IIb patients without history or symptoms of existing coronary heart disease with low HDL-cholesterol, elevated LDL-cholesterol, and elevated triglycerides unresponsive to weight loss, diet, exercise, and other pharmacologic agents","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopid","generic_name":"Gemfibrozil","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PPAR-alpha (Peroxisome Proliferator-Activated Receptor Alpha)","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"topotecan","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nogitecan","generic_name":"topotecan","company_name":"Novartis","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"topotecan","quality_score":80,"revenue":null,"mechanism":"Topotecan is a topoisomerase inhibitor that prevents DNA re-ligation, causing double-strand DNA damage."},{"drug_id":"sunitinib","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"sunitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":67,"revenue":null,"mechanism":"Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT."},{"drug_id":"menest","indication_name":"Prostatic carcinoma - palliative therapy of advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Menest","generic_name":"Estrogens, Esterified","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Esterified estrogens, sold under the brand names Estratab and Menest, are used for hormone therapy and cancer treatment."},{"drug_id":"covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older for the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Covid-19 Sterilizing","generic_name":"COVID-19 Vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older for the Moderna COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Covid-19 Sterilizing","generic_name":"COVID-19 Vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older for the Novavax COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Covid-19 Sterilizing","generic_name":"COVID-19 Vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older for the Janssen COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Covid-19 Sterilizing","generic_name":"COVID-19 Vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"prazosin-hcl","indication_name":"Reducing the risk of fatal and nonfatal cardiovascular events","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prazosin Hcl","generic_name":"prazosin-hcl","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1D","drug_class":"prazosin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"prazosin-hcl","indication_name":"Reducing the risk of stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prazosin Hcl","generic_name":"prazosin-hcl","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1D","drug_class":"prazosin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"prazosin-hcl","indication_name":"Reducing the risk of myocardial infarctions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prazosin Hcl","generic_name":"prazosin-hcl","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1D","drug_class":"prazosin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"prazosin-hcl","indication_name":"Reducing cardiovascular mortality","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prazosin Hcl","generic_name":"prazosin-hcl","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1D","drug_class":"prazosin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"sunitinib-malate","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sunitinib Malate","generic_name":"sunitinib-malate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":80,"revenue":null,"mechanism":"Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, including PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, and RET."},{"drug_id":"pertuzumab","indication_name":"HER2-positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Perjeta","generic_name":"pertuzumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"HER2/neu Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Pertuzumab targets the extracellular dimerization domain of the HER2 protein, blocking ligand-dependent heterodimerization with other HER family members."},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain))","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (subcutaneous injection)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age, 0.025 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age, 0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age, 0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age, 0.0125 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age, 0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age, 0.0125 mL dose for 6 months-4 years of age) (0.0125 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"aldactone","indication_name":"Long-term maintenance therapy for discrete aldosterone-producing adrenal adenomas in non-surgical candidates","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"Spironolactone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule","drug_class":"Potassium-sparing diuretic, aldosterone antagonist","quality_score":66,"revenue":null,"mechanism":"Aldosterone antagonist causing increased sodium and water excretion while retaining potassium."},{"drug_id":"enfortumab","indication_name":"Metastatic urothelial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Enfortumab","company_name":"Brigham and Women's Hospital","drug_phase":"phase_1","molecular_target":"Nectin-4, Tubulin beta","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Metastatic ovarian carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Metastatic transitional cell bladder carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Metastatic thyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Metastatic gastric carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Metastatic bronchogenic carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"pf-06823859","indication_name":"Squamous Cell Carcinoma of the Head and Neck (SCCHN) with disease progression on or after platinum-containing chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with axitinib.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with lenvatinib.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with pembrolizumab and lenvatinib.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with pembrolizumab and lenvatinib in patients with a PD-L1 CPS ≥ 10 as determined by an FDA-approved test.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"erismodegib","indication_name":"Basal cell carcinoma of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Erismodegib","company_name":"Washington University School of Medicine","drug_phase":"discontinued","molecular_target":"Smoothened homolog, Sonic hedgehog protein","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"First-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil and radiation therapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of adolescents 11 through 12 years of age","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of adolescents 13 through 18 years of age who have not previously completed the series","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Catch-up vaccination for individuals 13 through 18 years of age who have not previously completed the series","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of adults 19 through 26 years of age who have not previously completed the series","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Catch-up vaccination for adults 19 through 26 years of age who have not previously completed the series","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of adults 27 years of age and older who have not previously completed the series","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Catch-up vaccination for adults 27 years of age and older who have not previously completed the series","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"nexavar","indication_name":"Carcinoma of thyroid","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nexavar","company_name":"Fujian Medical University","drug_phase":"discontinued","molecular_target":"Citron Rho-interacting kinase, Cyclin-dependent kinase-like 2, Cyclin-dependent kinase-like 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"nexavar","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nexavar","company_name":"Fujian Medical University","drug_phase":"discontinued","molecular_target":"Citron Rho-interacting kinase, Cyclin-dependent kinase-like 2, Cyclin-dependent kinase-like 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"nexavar","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nexavar","company_name":"Fujian Medical University","drug_phase":"discontinued","molecular_target":"Citron Rho-interacting kinase, Cyclin-dependent kinase-like 2, Cyclin-dependent kinase-like 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"zactima","indication_name":"Carcinoma of thyroid","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zactima","company_name":"Barbara Ann Karmanos Cancer Institute","drug_phase":"discontinued","molecular_target":"AarF domain-containing protein kinase 4, Bone morphogenetic protein receptor type-1B, Chaperone activity of bc1 complex-like, mitochondrial","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"zactima","indication_name":"Medullary thyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zactima","company_name":"Barbara Ann Karmanos Cancer Institute","drug_phase":"discontinued","molecular_target":"AarF domain-containing protein kinase 4, Bone morphogenetic protein receptor type-1B, Chaperone activity of bc1 complex-like, mitochondrial","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"pf-06882961","indication_name":"Urothelial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06882961","generic_name":"pf-06882961","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":10,"revenue":null,"mechanism":"Not specified"},{"drug_id":"pd-0332991","indication_name":"Human epidermal growth factor 2 negative carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PD-0332991","generic_name":"pd-0332991","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase TAO2","drug_class":"PD-0332991, 125mg, 3 cycles","quality_score":null,"revenue":null,"mechanism":"PD-0332991, 125mg, 3 cycles"},{"drug_id":"adriacin","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriacin","indication_name":"Carcinoma of female breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriacin","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriacin","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"endometrin","indication_name":"Endometrial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Endometrin","generic_name":"progesterone","company_name":"Ferring","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1","drug_class":"Progesterone [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"pembrolizuma","indication_name":"Endometrial carcinoma progressing after chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pembrolizuma","company_name":"Memorial Sloan Kettering Cancer Center","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"pembrolizuma","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pembrolizuma","company_name":"Memorial Sloan Kettering Cancer Center","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"pembrolizuma","indication_name":"Squamous cell carcinoma of esophagus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pembrolizuma","company_name":"Memorial Sloan Kettering Cancer Center","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"pembrolizuma","indication_name":"Unresectable urothelial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pembrolizuma","company_name":"Memorial Sloan Kettering Cancer Center","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Carcinoma of female breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cabozantinib","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"CABOZANTINIB","company_name":"Exelixis Inc","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":53,"revenue":null,"mechanism":"Cometriq works by blocking the activity of vascular endothelial growth factor receptor 2, a protein involved in tumor growth and angiogenesis."},{"drug_id":"cabozantinib","indication_name":"Medullary thyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"CABOZANTINIB","company_name":"Exelixis Inc","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":53,"revenue":null,"mechanism":"Cometriq works by blocking the activity of vascular endothelial growth factor receptor 2, a protein involved in tumor growth and angiogenesis."},{"drug_id":"cabozantinib","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"CABOZANTINIB","company_name":"Exelixis Inc","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":53,"revenue":null,"mechanism":"Cometriq works by blocking the activity of vascular endothelial growth factor receptor 2, a protein involved in tumor growth and angiogenesis."},{"drug_id":"cabozantinib","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"CABOZANTINIB","company_name":"Exelixis Inc","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":53,"revenue":null,"mechanism":"Cometriq works by blocking the activity of vascular endothelial growth factor receptor 2, a protein involved in tumor growth and angiogenesis."},{"drug_id":"hycamtin","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hycamtin","company_name":"North Eastern German Society of Gynaecological Oncology","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 4, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"afinitor","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Afinitor","company_name":"Central European Society for Anticancer Drug Research","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"afinitor","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Afinitor","company_name":"Central European Society for Anticancer Drug Research","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"cyclophosphamid","indication_name":"Adenocarcinoma of the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"cyclophosphamid","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"trientine","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Syprine","generic_name":"TRIENTINE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 14","drug_class":"Copper Chelator","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"zenocutuzumab","indication_name":"advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bizengri","generic_name":"ZENOCUTUZUMAB","company_name":"Merus N.V.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Bizengri works by binding to a specific protein on cancer cells to block their growth and spread."},{"drug_id":"taxotere","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taxotere","company_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"taxotere","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taxotere","company_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"vinblastin","indication_name":"Carcinoma of female breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vinblastin","company_name":"The Lymphoma Academic Research Organisation","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"vinblastin","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vinblastin","company_name":"The Lymphoma Academic Research Organisation","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"yervoy","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yervoy","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"imfinzi","indication_name":"Extensive stage primary small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imfinzi","company_name":"University Medical Center Groningen","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"imfinzi","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imfinzi","company_name":"University Medical Center Groningen","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"imfinzi","indication_name":"Metastatic carcinoma to biliary tract","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imfinzi","company_name":"University Medical Center Groningen","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"imfinzi","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imfinzi","company_name":"University Medical Center Groningen","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"imfinzi","indication_name":"Transitional cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imfinzi","company_name":"University Medical Center Groningen","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"inlyta","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inlyta","generic_name":"Axitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3","drug_class":"Receptor tyrosine kinase inhibitor","quality_score":63,"revenue":null,"mechanism":"Axitinib inhibits VEGFR-1, VEGFR-2, and VEGFR-3 to block pathologic angiogenesis and tumor growth."},{"drug_id":"sutent","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"Sunitinib Malate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Receptor tyrosine kinases (RTKs): PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, RET","drug_class":"Small molecule kinase inhibitor","quality_score":67,"revenue":null,"mechanism":"Sunitinib inhibits multiple receptor tyrosine kinases implicated in tumor growth, angiogenesis, and metastatic progression."},{"drug_id":"trastuzumab-dkst","indication_name":"HER2-positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OGIVRI","generic_name":"TRASTUZUMAB-DKST","company_name":"MYLAN GMBH","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"HER2/neu Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"margetuximab-cmkb","indication_name":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MARGENZA","generic_name":"MARGETUXIMAB-CMKB","company_name":"MACROGENICS INC","drug_phase":"marketed","molecular_target":"Low affinity immunoglobulin gamma Fc region receptor III-A, Receptor tyrosine-protein kinase erbB-2","drug_class":"HER2/neu Receptor Antagonist [EPC]","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"tremelimumab-actl","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"IMJUDO","generic_name":"TREMELIMUMAB-ACTL","company_name":"ASTRAZENECA AB","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"retifanlimab-dlwr","indication_name":"Merkel cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ZYNYZ","generic_name":"RETIFANLIMAB-DLWR","company_name":"INCYTE CORP","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Anaplastic Thyroid Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Basal Cell Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"quadrivalent-influenza-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in people 6 months of age and older, when the circulating influenza A and B viruses are expected to be well matched to the vaccine viruses.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quadrivalent Influenza Vaccine","company_name":"International Centre for Diarrhoeal Disease Research, Bangladesh","drug_phase":"marketed","molecular_target":"Influenza viruses","drug_class":"Inactivated vaccine","quality_score":34,"revenue":null,"mechanism":"This vaccine works by stimulating the body's immune system to produce antibodies against influenza viruses."},{"drug_id":"formestane","indication_name":"Carcinoma of female breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lentaron","generic_name":"FORMESTANE","company_name":"","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"formestane","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"razoxane","indication_name":"Doxorubicin Induced Cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Razoxin","generic_name":"RAZOXANE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Razoxin works by chelating iron and preventing the formation of free radicals that damage heart tissue."},{"drug_id":"mitoxantrone","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."},{"drug_id":"estring","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estring","generic_name":"Estradiol","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Ovulation","drug_class":"Combined Oral Contraceptive (COC)","quality_score":71,"revenue":null,"mechanism":"Prevents pregnancy primarily by suppressing ovulation."},{"drug_id":"estring","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estring","generic_name":"Estradiol","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Ovulation","drug_class":"Combined Oral Contraceptive (COC)","quality_score":71,"revenue":null,"mechanism":"Prevents pregnancy primarily by suppressing ovulation."},{"drug_id":"estring","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estring","generic_name":"Estradiol","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Ovulation","drug_class":"Combined Oral Contraceptive (COC)","quality_score":71,"revenue":null,"mechanism":"Prevents pregnancy primarily by suppressing ovulation."},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of hepatocellular carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"trastuzuma","indication_name":"HER2-positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Trastuzuma","company_name":"Fudan University","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2, Tubulin beta","drug_class":"","quality_score":11,"revenue":null,"mechanism":null},{"drug_id":"votrient","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Votrient","company_name":"Tracon Pharmaceuticals Inc.","drug_phase":"marketed","molecular_target":"Bone morphogenetic protein receptor type-1B, Cyclin-dependent kinase 11A, Cyclin-dependent kinase 11B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"besilesomab","indication_name":"Nuclear medicine imaging procedure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Scintimun","generic_name":"BESILESOMAB","company_name":"CIS bio international","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"myoinositol","indication_name":"Niacin deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Myoinositol","company_name":"University of Colorado, Denver","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"lynparza","indication_name":"Human epidermal growth factor 2 negative carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lynparza","company_name":"University of Texas Southwestern Medical Center","drug_phase":"marketed","molecular_target":"Mono [ADP-ribose] polymerase PARP16, Tankyrase-1, Tankyrase-2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"docetaxol","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Docetaxol","company_name":"Fudan University","drug_phase":"phase_2","molecular_target":"Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"docetaxol","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Docetaxol","company_name":"Fudan University","drug_phase":"phase_2","molecular_target":"Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxyurea","indication_name":"Locally advanced squamous cell carcinomas of the head and neck (excluding lip) in combination with concurrent chemoradiation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"HYDROXYUREA","company_name":"","drug_phase":"marketed","molecular_target":"Ribonucleotide reductase","drug_class":"Antimetabolite [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"fytic-acid","indication_name":"Lymphoscintigraphy in cervical cancer, uterine neoplasms, vulvar cancer, and head and neck canccer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phyliance","generic_name":"fytic acid","company_name":"PDRadiopharma Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"padcev","indication_name":"Metastatic urothelial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enfortumab","generic_name":"padcev","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Nectin-4","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"nicotinyl-alcohol","indication_name":"Niacin deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyridylcarbinol","generic_name":"nicotinyl alcohol","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"nicotinyl alcohol","quality_score":null,"revenue":null,"mechanism":"Pyridylcarbinol works by providing the body with a precursor to NAD+, a crucial coenzyme involved in energy metabolism."},{"drug_id":"gemcitabine","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gemzar","generic_name":"gemcitabine","company_name":"Accord Hlthcare","drug_phase":"marketed","molecular_target":"DNA polymerase (alpha/delta/epsilon)","drug_class":"Nucleoside Metabolic Inhibitor","quality_score":75,"revenue":null,"mechanism":"Gemzar works by mimicking a building block of DNA, tricking cancer cells into incorporating it into their DNA and then stopping the replication process."},{"drug_id":"gemcitabine","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gemzar","generic_name":"gemcitabine","company_name":"Accord Hlthcare","drug_phase":"marketed","molecular_target":"DNA polymerase (alpha/delta/epsilon)","drug_class":"Nucleoside Metabolic Inhibitor","quality_score":75,"revenue":null,"mechanism":"Gemzar works by mimicking a building block of DNA, tricking cancer cells into incorporating it into their DNA and then stopping the replication process."},{"drug_id":"irinotecan","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Camptosar","generic_name":"irinotecan","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I","drug_class":"Topoisomerase Inhibitor","quality_score":76,"revenue":null,"mechanism":"Irinotecan and its metabolite SN-38 bind to the topoisomerase I-DNA complex, preventing DNA repair and causing double-strand breaks."},{"drug_id":"cerliponase-alfa","indication_name":"Late-infantile neuronal ceroid lipofuscinosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rhttp1","generic_name":"CERLIPONASE ALFA","company_name":"BioMarin","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal N-terminal Tripeptidyl Peptidase","quality_score":10,"revenue":null,"mechanism":"Cerliponase alfa works by inhibiting the breakdown of a protein called tripeptidyl peptidase, which is deficient in patients with late-infantile neuronal ceroid lipofuscinosis."},{"drug_id":"histrelin","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantas","generic_name":"HISTRELIN","company_name":"","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"Gonadotropin Releasing Hormone Receptor Agonist","quality_score":75,"revenue":null,"mechanism":"Vantas works by binding to the gonadotropin-releasing hormone receptor, mimicking the natural hormone and reducing the production of sex hormones."},{"drug_id":"imipenem","indication_name":"Infection caused by Acinetobacter spp resistant to carbapenem antimicrobial drugs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Primaxin","generic_name":"IMIPENEM","company_name":"Merck Sharp & Dohme B.V.","drug_phase":"marketed","molecular_target":"","drug_class":"imipenem","quality_score":70,"revenue":null,"mechanism":"Primaxin works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"amikacin","indication_name":"Complicated Urinary Tract Infection due to Acinetobacter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arikayce Kit","generic_name":"AMIKACIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial","quality_score":10,"revenue":null,"mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria."},{"drug_id":"amikacin","indication_name":"Nontuberculous mycobacterial pulmonary disease caused by amikacin-sensitive Mycobacteriumavium complex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arikayce Kit","generic_name":"AMIKACIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial","quality_score":10,"revenue":null,"mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria."},{"drug_id":"fluorouracil","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carac","generic_name":"fluorouracil","company_name":"Extrovis","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"fluorouracil","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carac","generic_name":"fluorouracil","company_name":"Extrovis","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"fluorouracil","indication_name":"Superficial basal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carac","generic_name":"fluorouracil","company_name":"Extrovis","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"estradiol-cypionate","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depoestradiol","generic_name":"ESTRADIOL CYPIONATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor beta","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"estradiol-cypionate","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depoestradiol","generic_name":"ESTRADIOL CYPIONATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor beta","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"megestrol-acetate","indication_name":"Endometrial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Megace","generic_name":"MEGESTROL ACETATE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Progestin","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"nicotine","indication_name":"Niacin deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nicorette","generic_name":"NICOTINE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor; alpha4/beta2","drug_class":"Cholinergic Nicotinic Agonist [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"torisel","indication_name":"advanced renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Torisel","generic_name":"Temsirolimus","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1","drug_class":"temsirolimus","quality_score":10,"revenue":null,"mechanism":"Temsirolimus is an inhibitor of mTOR, a protein that controls cell division."},{"drug_id":"leuprolide-acetate","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leuprolide Acetate","generic_name":"leuprolide-acetate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"leuprorelin","quality_score":10,"revenue":null,"mechanism":"Leuprolide acetate is a manufactured version of a hormone that regulates growth and development, used to treat hormone-related conditions."},{"drug_id":"bcg","indication_name":"Treatment of carcinoma in situ (CIS) of the urinary bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC))","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"retifanlimab","indication_name":"Merkel cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zynyz","generic_name":"RETIFANLIMAB","company_name":"Incyte Corp","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Zynyz works by blocking the PD-1 receptor on immune cells, allowing them to recognize and attack cancer cells."},{"drug_id":"lurbinectedin","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zepzelca","generic_name":"LURBINECTEDIN","company_name":"Jazz Pharmaceuticals","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Zepzelca works by attaching an alkyl group to DNA, which interferes with DNA replication and causes cell death."},{"drug_id":"irinotecan-hydrochloride","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Camptosar","generic_name":"Irinotecan Hydrochloride","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"Topoisomerase Inhibitor","quality_score":79,"revenue":null,"mechanism":"Camptosar works by blocking the enzyme topoisomerase I, which is necessary for DNA replication, thereby preventing cancer cells from dividing and growing."},{"drug_id":"erlotinib","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tarceva","generic_name":"erlotinib","company_name":"Osi Pharms","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Tarceva works by blocking the epidermal growth factor receptor, a protein that helps cancer cells grow."},{"drug_id":"cilastatin","indication_name":"Infection caused by Acinetobacter spp resistant to carbapenem antimicrobial drugs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Primaxin","generic_name":"CILASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dipeptidase 1","drug_class":"Renal Dehydropeptidase Inhibitor","quality_score":65,"revenue":null,"mechanism":"Primaxin works by inhibiting the action of dehydropeptidase, an enzyme that breaks down certain antibiotics, thereby protecting them from degradation and allowing them to reach effective concentrations in the body."},{"drug_id":"mitotane","indication_name":"Carcinoma in situ of adrenal cortex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lysodren","generic_name":"MITOTANE","company_name":"Esteve","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6","drug_class":"mitotane","quality_score":70,"revenue":null,"mechanism":"Lysodren works by inhibiting the production of cortisol and aldosterone in the adrenal cortex."},{"drug_id":"relebactam","indication_name":"Infection caused by Acinetobacter spp resistant to carbapenem antimicrobial drugs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Recarbrio","generic_name":"RELEBACTAM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Renal Dehydropeptidase Inhibitor [EPC]","quality_score":34,"revenue":null,"mechanism":"Recarbrio works by inhibiting the beta-lactamase enzymes produced by certain bacteria, allowing carbapenem antibiotics to effectively target and kill the bacteria."},{"drug_id":"durlobactam","indication_name":"Hospital-acquired bacterial pneumonia caused by acinetobacter baumannii-calcoaceticus complex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xacduro (Copackaged)","generic_name":"DURLOBACTAM","company_name":"Entasis Therap","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor","quality_score":45,"revenue":null,"mechanism":"Xacduro works by binding to and inhibiting bacterial beta-lactamases, allowing antibiotics to effectively kill bacteria."},{"drug_id":"durlobactam","indication_name":"Infection caused by carbapenem-resistant acinetobacter baumannii-calcoaceticus complex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xacduro (Copackaged)","generic_name":"DURLOBACTAM","company_name":"Entasis Therap","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor","quality_score":45,"revenue":null,"mechanism":"Xacduro works by binding to and inhibiting bacterial beta-lactamases, allowing antibiotics to effectively kill bacteria."},{"drug_id":"durlobactam","indication_name":"Ventilator-associated bacterial pneumonia caused by acinetobacter baumannii-calcoaceticus complex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xacduro (Copackaged)","generic_name":"DURLOBACTAM","company_name":"Entasis Therap","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor","quality_score":45,"revenue":null,"mechanism":"Xacduro works by binding to and inhibiting bacterial beta-lactamases, allowing antibiotics to effectively kill bacteria."},{"drug_id":"trazimera","indication_name":"HER2-positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Herceptin","generic_name":"Trastuzumab-Qyyp","company_name":"Roche","drug_phase":"marketed","molecular_target":"HER2 (c-erbB2) proto-oncogene transmembrane receptor protein","drug_class":"HER2/neu receptor antagonist monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Trastuzumab inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity."},{"drug_id":"aldesleukin","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Proleukin","generic_name":"ALDESLEUKIN","company_name":"Chiron","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"Lymphocyte Growth Factor [EPC]","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"disitamab-vedotin","indication_name":"Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Disitamab vedotin","generic_name":"disitamab-vedotin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"human epidermal growth factor receptor 2 (HER2)","drug_class":"antibody-drug conjugate","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"disitamab-vedotin","indication_name":"Locally advanced or metastatic esophageal squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Disitamab vedotin","generic_name":"disitamab-vedotin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"human epidermal growth factor receptor 2 (HER2)","drug_class":"antibody-drug conjugate","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Carcinoma of female breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"dalfopristin","indication_name":"Vancomycin resistant enterococcus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Synercid","generic_name":"DALFOPRISTIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Streptogramin Antibacterial","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"capecitabine","indication_name":"Treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"temoporfin","indication_name":"Squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foscan","generic_name":"TEMOPORFIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"temoporfin","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"anti-ox40-antibody-pf-04518600","indication_name":"Hepatocellular carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anti-OX40 Antibody PF-04518600","generic_name":"anti-ox40-antibody-pf-04518600","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"OX40 receptor","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"axitinib-ag-013736","indication_name":"Advanced renal cell carcinoma (RCC) after failure of prior therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Axitinib (AG-013736)","generic_name":"axitinib-ag-013736","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"vascular endothelial growth factor receptors (VEGFRs)","drug_class":"tyrosine kinase inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"axitinib-ag-013736","indication_name":"Advanced renal cell carcinoma (RCC) as a first-line treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Axitinib (AG-013736)","generic_name":"axitinib-ag-013736","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"vascular endothelial growth factor receptors (VEGFRs)","drug_class":"tyrosine kinase inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a third dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a third dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a third dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a fourth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a fourth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a fourth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a fifth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a fifth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a fifth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a sixth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a sixth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a sixth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a seventh dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a seventh dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a seventh dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as an eighth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as an eighth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as an eighth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine, and when administered to individuals who have completed primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine, and when administered to individuals who have completed primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine, and when administered to individuals who have completed primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older who have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"infigratinib","indication_name":"Unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Truseltiq","generic_name":"INFIGRATINIB","company_name":"Helsinn Hlthcare","drug_phase":"marketed","molecular_target":"Fibroblast growth factor receptor 2","drug_class":"","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"linezolid","indication_name":"Vancomycin resistant enterococcus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyvox","generic_name":"linezolid","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Amine oxidase [flavin-containing] A","drug_class":"Oxazolidinone Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Zyvox works by inhibiting the bacterial protein synthesis initiation complex, preventing the growth and replication of Gram-positive bacteria."},{"drug_id":"linezolid","indication_name":"Vancomycin-Resistant Enterococcus Faecium Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyvox","generic_name":"linezolid","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Amine oxidase [flavin-containing] A","drug_class":"Oxazolidinone Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Zyvox works by inhibiting the bacterial protein synthesis initiation complex, preventing the growth and replication of Gram-positive bacteria."},{"drug_id":"bicalutamide","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Casodex","generic_name":"bicalutamide","company_name":"ANI Pharmaceuticals","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen Receptor Inhibitor [EPC]","quality_score":10,"revenue":null,"mechanism":"Casodex works by blocking the androgen receptor, a protein that helps prostate cancer cells grow."},{"drug_id":"sirolimus","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rapamune","generic_name":"sirolimus","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"mTOR Inhibitor Immunosuppressant [EPC]","quality_score":80,"revenue":null,"mechanism":"Rapamune works by binding to the mTOR protein, inhibiting its activity and preventing the growth and proliferation of certain cells."},{"drug_id":"docetaxel","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxotere","generic_name":"Docetaxel","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Growth hormone-releasing hormone receptor","drug_class":"Microtubule Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Taxotere works by binding to microtubules, preventing them from disassembling and thereby blocking cell division."},{"drug_id":"docetaxel","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxotere","generic_name":"Docetaxel","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Growth hormone-releasing hormone receptor","drug_class":"Microtubule Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Taxotere works by binding to microtubules, preventing them from disassembling and thereby blocking cell division."},{"drug_id":"pralsetinib","indication_name":"Medullary thyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gavreto","generic_name":"PRALSETINIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"RET","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Pralsetinib inhibits RET kinase and its oncogenic fusions/mutations, blocking downstream signaling and reducing tumor growth."},{"drug_id":"onivyde","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Camptosar","generic_name":"onivyde","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"Topoisomerase Inhibitor","quality_score":74,"revenue":null,"mechanism":"Camptosar works by inhibiting topoisomerase I, an enzyme that helps DNA replicate, causing DNA damage and cancer cell death."},{"drug_id":"pf-06865571","indication_name":"Urothelial Carcinoma (UC) in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Urothelial Carcinoma (UC) in adults in combination with pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Head and Neck Squamous Cell Carcinoma (HNSCC) in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Head and Neck Squamous Cell Carcinoma (HNSCC) in adults in combination with pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"degarelix","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Firmagon","generic_name":"degarelix","company_name":"Ferring","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"Gonadotropin Releasing Hormone Receptor Antagonist","quality_score":75,"revenue":null,"mechanism":"Firmagon works by blocking the action of gonadotropin-releasing hormone on the pituitary gland, which reduces testosterone production."},{"drug_id":"vismodegib","indication_name":"Basal cell carcinoma of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Erivedge","generic_name":"vismodegib","company_name":"Roche","drug_phase":"marketed","molecular_target":"Smoothened","drug_class":"Hedgehog Pathway Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Vismodegib inhibits the Hedgehog pathway by binding to and blocking Smoothened, a key protein in the pathway."},{"drug_id":"doxorubicin","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"doxorubicin","indication_name":"Carcinoma of female breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"doxorubicin","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"doxorubicin","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"dexrazoxane","indication_name":"Doxorubicin Induced Cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zinecard","generic_name":"DEXRAZOXANE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA topoisomerase 2-alpha","drug_class":"Cytoprotective Agent","quality_score":10,"revenue":null,"mechanism":"Zinecard works by binding to metal ions and preventing them from causing damage to DNA during anthracycline treatment."},{"drug_id":"futibatinib","indication_name":"Intrahepatic cholangiocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lytgobi","generic_name":"futibatinib","company_name":"Taiho Oncology","drug_phase":"marketed","molecular_target":"Fibroblast growth factor receptor 2","drug_class":"","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"triptorelin","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trelstar","generic_name":"triptorelin","company_name":"Verity","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"Gonadotropin Releasing Hormone Receptor Agonist","quality_score":70,"revenue":null,"mechanism":"Trelstar works by binding to and activating the gonadotropin-releasing hormone receptor, which leads to a decrease in testosterone production."},{"drug_id":"imiquimod","indication_name":"Superficial basal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldara","generic_name":"IMIQUIMOD","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"7,8-dihydro-8-oxoguanine triphosphatase","drug_class":"imiquimod","quality_score":75,"revenue":null,"mechanism":"Aldara works by activating the immune system to recognize and attack abnormal cells."},{"drug_id":"chembl-chembl1200796","indication_name":"Adenocarcinoma of the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"chembl-chembl1200796","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"methotrexate","indication_name":"Carcinoma of female breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trexall","generic_name":"methotrexate","company_name":"Generic (originally Lederle Laboratories)","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4","drug_class":"Antifolate, DMARD","quality_score":55,"revenue":null,"mechanism":"Antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis at high doses (oncology) and suppressing inflammation at low doses (autoimmune)."},{"drug_id":"levofloxacin","indication_name":"Otitis externa caused by Acinetobacter spp.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levaquin","generic_name":"levofloxacin","company_name":"Generic (originally Daiichi Sankyo/J&J)","drug_phase":"marketed","molecular_target":"CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2","drug_class":"Fluoroquinolone Antibacterial [EPC]","quality_score":65,"revenue":null,"mechanism":"Levofloxacin is a fluoroquinolone antibacterial agent."},{"drug_id":"levofloxacin","indication_name":"Otitis media caused by Acinetobacter spp.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levaquin","generic_name":"levofloxacin","company_name":"Generic (originally Daiichi Sankyo/J&J)","drug_phase":"marketed","molecular_target":"CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2","drug_class":"Fluoroquinolone Antibacterial [EPC]","quality_score":65,"revenue":null,"mechanism":"Levofloxacin is a fluoroquinolone antibacterial agent."},{"drug_id":"firmagon","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Firmagon","company_name":"Centre Leon Berard","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methotrexat","indication_name":"Carcinoma of female breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methotrexat","company_name":"Biocad","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tamoxifen","indication_name":"Carcinoma of female breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nolvadex","generic_name":"tamoxifen","company_name":"AstraZeneca (originally ICI)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase, 5-hydroxytryptamine receptor 6","drug_class":"SERM (Selective estrogen receptor modulator)","quality_score":55,"revenue":null,"mechanism":"Selective estrogen receptor modulator (SERM) that blocks estrogen signaling in breast tissue while preserving bone density."},{"drug_id":"tamoxifen","indication_name":"Infiltrating duct carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nolvadex","generic_name":"tamoxifen","company_name":"AstraZeneca (originally ICI)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase, 5-hydroxytryptamine receptor 6","drug_class":"SERM (Selective estrogen receptor modulator)","quality_score":55,"revenue":null,"mechanism":"Selective estrogen receptor modulator (SERM) that blocks estrogen signaling in breast tissue while preserving bone density."},{"drug_id":"tamoxifen","indication_name":"Prevention of Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nolvadex","generic_name":"tamoxifen","company_name":"AstraZeneca (originally ICI)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase, 5-hydroxytryptamine receptor 6","drug_class":"SERM (Selective estrogen receptor modulator)","quality_score":55,"revenue":null,"mechanism":"Selective estrogen receptor modulator (SERM) that blocks estrogen signaling in breast tissue while preserving bone density."},{"drug_id":"herceptin","indication_name":"HER2-positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Herceptin","company_name":"National Cancer Institute (NCI)","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunomycin","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunomycin","indication_name":"Carcinoma of female breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunomycin","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunomycin","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"proleukin","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Proleukin","company_name":"University of Minnesota","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"trastuzumab-herceptin","indication_name":"HER2-positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trastuzumab (Herceptin)","generic_name":"trastuzumab-herceptin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"eligard","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eligard","company_name":"Astellas Pharma Europe Ltd.","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor, Gonadotropin-releasing hormone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xeloda","indication_name":"Lymph Node Positive Colorectal Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xeloda","company_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xeloda","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xeloda","company_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"progesteron","indication_name":"Endometrial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Progesteron","company_name":"Minia University","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zoladex","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zoladex","company_name":"University of Michigan Rogel Cancer Center","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor, Lutropin-choriogonadotropic hormone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"caprelsa","indication_name":"Carcinoma of thyroid","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Caprelsa","company_name":"Genzyme, a Sanofi Company","drug_phase":"marketed","molecular_target":"AarF domain-containing protein kinase 4, Bone morphogenetic protein receptor type-1B, Chaperone activity of bc1 complex-like, mitochondrial","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"caprelsa","indication_name":"Medullary thyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Caprelsa","company_name":"Genzyme, a Sanofi Company","drug_phase":"marketed","molecular_target":"AarF domain-containing protein kinase 4, Bone morphogenetic protein receptor type-1B, Chaperone activity of bc1 complex-like, mitochondrial","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"epidoxorubicin","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Epidoxorubicin","company_name":"Hoffmann-La Roche","drug_phase":"phase_2","molecular_target":"Tyrosine-protein kinase Fyn, 5-hydroxytryptamine receptor 4, Genome polyprotein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"megestrol","indication_name":"Endometrial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"megestrol","company_name":"National Center for Research Resources (NCRR)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C9, Multidrug resistance protein 1, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"abraxane","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abraxane","company_name":"The First Affiliated Hospital with Nanjing Medical University","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"abraxane","indication_name":"Carcinoma of fallopian tube","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abraxane","company_name":"The First Affiliated Hospital with Nanjing Medical University","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"abraxane","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abraxane","company_name":"The First Affiliated Hospital with Nanjing Medical University","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Carcinoma of female breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tarceva","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tarceva","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"AarF domain-containing protein kinase 4, Acyl-CoA dehydrogenase family member 11, Chaperone activity of bc1 complex-like, mitochondrial","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"rapamycin","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rapamycin","company_name":"Institut National de la Santé Et de la Recherche Médicale, France","drug_phase":"marketed","molecular_target":"Peptidyl-prolyl cis-trans isomerase FKBP3, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"etoposid","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Etoposid","company_name":"University of Ulm","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2, Multidrug resistance-associated protein 6","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"erbitux","indication_name":"Squamous cell carcinoma of larynx","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Erbitux","company_name":"Hellenic Oncology Research Group","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"erbitux","indication_name":"Squamous cell carcinoma of mouth","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Erbitux","company_name":"Hellenic Oncology Research Group","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"erbitux","indication_name":"Squamous cell carcinoma of nose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Erbitux","company_name":"Hellenic Oncology Research Group","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"erbitux","indication_name":"Squamous cell carcinoma of pharynx","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Erbitux","company_name":"Hellenic Oncology Research Group","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"taxol","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taxol","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"taxol","indication_name":"Carcinoma of fallopian tube","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taxol","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"taxol","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taxol","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"raloxifen","indication_name":"Prevention of Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"raloxifen","company_name":"Organon and Co","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, HLA class I histocompatibility antigen, A-3 alpha chain, 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zepzelca","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zepzelca","company_name":"Jazz Pharmaceuticals","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zinecard","indication_name":"Doxorubicin Induced Cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zinecard","company_name":"M.D. Anderson Cancer Center","drug_phase":"phase_1","molecular_target":"DNA topoisomerase 2-beta, DNA topoisomerase 2-alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mitozantrone","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mitozantrone","company_name":"US Department of Veterans Affairs","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family G member 2, DNA-(apurinic or apyrimidinic site) lyase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"triptoreline","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Triptoreline","company_name":"Universitaire Ziekenhuizen KU Leuven","drug_phase":"phase_2","molecular_target":"Gonadotropin-releasing hormone receptor, Gonadotropin-releasing hormone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"perjeta","indication_name":"HER2-positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Perjeta","company_name":"BioRay Pharmaceutical Co., Ltd.","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"capecitabine","indication_name":"Adjuvant treatment of pancreatic adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."},{"drug_id":"bevacizumab-maly","indication_name":"Metastatic Renal Cell Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"torisel","indication_name":"Advanced renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Torisel","generic_name":"Temsirolimus","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1","drug_class":"temsirolimus","quality_score":10,"revenue":null,"mechanism":"Temsirolimus is an inhibitor of mTOR, a protein that controls cell division."},{"drug_id":"mitomycin","indication_name":"Disseminated adenocarcinoma of the stomach or pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mitozytrex","generic_name":"MITOMYCIN","company_name":"Kyowa Kirin Co., Ltd.","drug_phase":"marketed","molecular_target":"Indoleamine 2,3-dioxygenase 1","drug_class":"Alkylating Drug [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"mitomycin","indication_name":"Palliative treatment for disseminated adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mitozytrex","generic_name":"MITOMYCIN","company_name":"Kyowa Kirin Co., Ltd.","drug_phase":"marketed","molecular_target":"Indoleamine 2,3-dioxygenase 1","drug_class":"Alkylating Drug [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"sunitinib","indication_name":"Advanced Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"sunitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":67,"revenue":null,"mechanism":"Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT."},{"drug_id":"chembl-chembl185","indication_name":"Superficial Basal Cell Carcinomas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLUOROURACIL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Advanced Renal Cell Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"First-Line Unresectable or Metastatic Hepatocellular Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Previously Treated Unresectable or Metastatic Hepatocellular Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3833373","indication_name":"Metastatic Merkel Cell Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AVELUMAB","company_name":"","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Avelumab binds to PD-L1, blocking its interaction with PD-1 and B7.1 receptors, restoring immune responses against tumors."},{"drug_id":"chembl-chembl3833373","indication_name":"First-Line Maintenance Urothelial Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AVELUMAB","company_name":"","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Avelumab binds to PD-L1, blocking its interaction with PD-1 and B7.1 receptors, restoring immune responses against tumors."},{"drug_id":"chembl-chembl3833373","indication_name":"Previously-Treated Urothelial Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AVELUMAB","company_name":"","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Avelumab binds to PD-L1, blocking its interaction with PD-1 and B7.1 receptors, restoring immune responses against tumors."},{"drug_id":"chembl-chembl3833373","indication_name":"Advanced Renal Cell Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AVELUMAB","company_name":"","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Avelumab binds to PD-L1, blocking its interaction with PD-1 and B7.1 receptors, restoring immune responses against tumors."},{"drug_id":"chembl-chembl1946170","indication_name":"Hepatocellular Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"REGORAFENIB","company_name":"","drug_phase":"marketed","molecular_target":"RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Regorafenib inhibits multiple kinases involved in oncogenesis, angiogenesis, metastasis, and tumor immunity."},{"drug_id":"telotristat-ethyl","indication_name":"Carcinoid Syndrome Diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TELOTRISTAT ETHYL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl359744","indication_name":"Metastatic Ovarian Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"chembl-chembl359744","indication_name":"Metastatic Transitional Cell Bladder Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"chembl-chembl359744","indication_name":"Metastatic Thyroid Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"chembl-chembl359744","indication_name":"Metastatic Gastric Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"chembl-chembl359744","indication_name":"Metastatic Bronchogenic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"sodium-iodide-i-131","indication_name":"Thyroid Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SODIUM IODIDE I 131","company_name":"","drug_phase":"marketed","molecular_target":"sodium-iodide symporter (NIS), thyroid peroxidase","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Iodide is transported and concentrated in thyroid cells, oxidized to iodinium, and used to iodinate thyroglobulin, with I-131's beta emission causing the therapeutic effect."},{"drug_id":"chembl-chembl428647","indication_name":"Advanced ovarian carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PACLITAXEL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Microtubule Inhibitor [EPC]","quality_score":37,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl428647","indication_name":"First-line ovarian carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PACLITAXEL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Microtubule Inhibitor [EPC]","quality_score":37,"revenue":null,"mechanism":null},{"drug_id":"doxycycline","indication_name":"Infections caused by Acinetobacter species","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bacillus-calmette-guerin","indication_name":"Treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bacillus-calmette-guerin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mycobacterium tuberculosis","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"thiabendazole","indication_name":"Infection by Uncinaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bovizole","generic_name":"THIABENDAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"Cytochrome P450 1A2","drug_class":"Anthelmintic","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"testolactone","indication_name":"Carcinoma of female breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Teolit","generic_name":"TESTOLACTONE","company_name":"","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase Inhibitor","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"inositol","indication_name":"Niacin deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inosital","generic_name":"INOSITOL","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"inositol","quality_score":null,"revenue":null,"mechanism":"Inosital works by influencing the metabolism of lipids in the body."},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Head and neck squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Urothelial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Merkel cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic esophageal squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic hepatocellular carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic cholangiocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic cutaneous squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"licensed-influenza-vaccine","indication_name":"Influenza vaccination","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Assorted Licensed Hand Sanitizer Grape 01","generic_name":"Licensed influenza vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"vaccine","quality_score":55,"revenue":null,"mechanism":"The mechanism of action is not specified."},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib and in patients who are not eligible for pembrolizumab plus axicabtagene ciloleucel","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib and in patients who are not eligible for pembrolizumab plus axicabtagene ciloleucel and in patients who are not eligible for pembrolizumab plus sacituzumab govitecan","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib and in patients who are not eligible for pembrolizumab plus axicabtagene ciloleucel and in patients who are not eligible for pembrolizumab plus sacituzumab govitecan and in patients who are not eligible for pembrolizumab plus atezolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib and in patients who are not eligible for pembrolizumab plus axicabtagene ciloleucel and in patients who are not eligible for pembrolizumab plus sacituzumab govitecan and in patients who are not eligible for pembrolizumab plus atezolizumab and in patients who are not eligible for pembrolizumab plus nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib and in patients who are not eligible for pembrolizumab plus axicabtagene ciloleucel and in patients who are not eligible for pembrolizumab plus sacituzumab govitecan and in patients who are not eligible for pembrolizumab plus atezolizumab and in patients who are not eligible for pembrolizumab plus nivolumab and in patients who are not eligible for pembrolizumab plus avelumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib and in patients who are not eligible for pembrolizumab plus axicabtagene ciloleucel and in patients who are not eligible for pembrolizumab plus sacituzumab govitecan and in patients who are not eligible for pembrolizumab plus atezolizumab and in patients who are not eligible for pembrolizumab plus nivolumab and in patients who are not eligible for pembrolizumab plus avelumab and in patients who are not eligible for pembrolizumab plus durvalumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib and in patients who are not eligible for pembrolizumab plus axicabtagene ciloleucel and in patients who are not eligible for pembrolizumab plus sacituzumab govitecan and in patients who are not eligible for pembrolizumab plus atezolizumab and in patients who are not eligible for pembrolizumab plus nivolumab and in patients who are not eligible for pembrolizumab plus avelumab and in patients who are not eligible for pembrolizumab plus durvalumab and in patients who are not eligible for pembrolizumab plus sacituzumab govitecan plus cetrelimab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tryptorelin","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tryptorelin","company_name":"Instituto Valenciano de Infertilidad, IVI VALENCIA","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor, Gonadotropin-releasing hormone receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"toremifene","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fareston","generic_name":"TOREMIFENE","company_name":"Kyowa Kirin","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6","drug_class":"Estrogen Agonist/Antagonist","quality_score":64,"revenue":null,"mechanism":"Fareston works by binding to estrogen receptors in the body, which can help reduce the growth of breast cancer cells."},{"drug_id":"estradiol-valerate","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Delestrogen","generic_name":"ESTRADIOL VALERATE","company_name":"Ph Health","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":65,"revenue":null,"mechanism":"Delestrogen works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."},{"drug_id":"estradiol-valerate","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Delestrogen","generic_name":"ESTRADIOL VALERATE","company_name":"Ph Health","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":65,"revenue":null,"mechanism":"Delestrogen works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."},{"drug_id":"5-fu","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carac","generic_name":"5-fu","company_name":"Spectrum Pharms","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Nucleoside Metabolic Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"5-fu","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carac","generic_name":"5-fu","company_name":"Spectrum Pharms","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Nucleoside Metabolic Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"5-fu","indication_name":"Superficial basal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carac","generic_name":"5-fu","company_name":"Spectrum Pharms","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Nucleoside Metabolic Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"leuprorelin","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lupron","generic_name":"leuprorelin","company_name":"Accord Healthcare S.L.U.","drug_phase":"marketed","molecular_target":"GnRH receptors","drug_class":"Gonadotropin Releasing Hormone Receptor Agonist","quality_score":65,"revenue":null,"mechanism":"Leuprolide acetate, a long-acting GnRH analog, initially stimulates then suppresses pituitary gonadotropins, reducing gonadal steroid secretion."},{"drug_id":"capecitabine","indication_name":"Lymph Node Positive Colorectal Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."},{"drug_id":"capecitabine","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."},{"drug_id":"lapatinib","indication_name":"HER2-positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tykerb","generic_name":"LAPATINIB","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"Kinase Inhibitor","quality_score":68,"revenue":null,"mechanism":"Tykerb works by blocking the epidermal growth factor receptor, a protein that promotes cancer cell growth."},{"drug_id":"vandetanib","indication_name":"Carcinoma of thyroid","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caprelsa","generic_name":"VANDETANIB","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Receptor-interacting serine/threonine-protein kinase 2","drug_class":"Kinase Inhibitor [EPC]","quality_score":64,"revenue":null,"mechanism":"Caprelsa works by blocking a specific protein that helps cancer cells grow and spread."},{"drug_id":"vandetanib","indication_name":"Medullary thyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caprelsa","generic_name":"VANDETANIB","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Receptor-interacting serine/threonine-protein kinase 2","drug_class":"Kinase Inhibitor [EPC]","quality_score":64,"revenue":null,"mechanism":"Caprelsa works by blocking a specific protein that helps cancer cells grow and spread."},{"drug_id":"cetuximab","indication_name":"Squamous cell carcinoma of larynx","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Erbitux","generic_name":"cetuximab","company_name":"Imclone","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"Epidermal Growth Factor Receptor Antagonist [EPC]","quality_score":62,"revenue":null,"mechanism":"Erbitux works by binding to the Epidermal Growth Factor Receptor (EGFR) on cancer cells, blocking the receptor's ability to stimulate cell growth and division."},{"drug_id":"cetuximab","indication_name":"Squamous cell carcinoma of mouth","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Erbitux","generic_name":"cetuximab","company_name":"Imclone","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"Epidermal Growth Factor Receptor Antagonist [EPC]","quality_score":62,"revenue":null,"mechanism":"Erbitux works by binding to the Epidermal Growth Factor Receptor (EGFR) on cancer cells, blocking the receptor's ability to stimulate cell growth and division."},{"drug_id":"cetuximab","indication_name":"Squamous cell carcinoma of nose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Erbitux","generic_name":"cetuximab","company_name":"Imclone","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"Epidermal Growth Factor Receptor Antagonist [EPC]","quality_score":62,"revenue":null,"mechanism":"Erbitux works by binding to the Epidermal Growth Factor Receptor (EGFR) on cancer cells, blocking the receptor's ability to stimulate cell growth and division."},{"drug_id":"cetuximab","indication_name":"Squamous cell carcinoma of pharynx","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Erbitux","generic_name":"cetuximab","company_name":"Imclone","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"Epidermal Growth Factor Receptor Antagonist [EPC]","quality_score":62,"revenue":null,"mechanism":"Erbitux works by binding to the Epidermal Growth Factor Receptor (EGFR) on cancer cells, blocking the receptor's ability to stimulate cell growth and division."},{"drug_id":"rapamune","indication_name":"Renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rapamune","company_name":"Wyeth is now a wholly owned subsidiary of Pfizer","drug_phase":"marketed","molecular_target":"Peptidyl-prolyl cis-trans isomerase FKBP3, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"enhertu","indication_name":"Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Enhertu","company_name":"Washington D.C. Veterans Affairs Medical Center","drug_phase":"marketed","molecular_target":"DNA topoisomerase 1, Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"enhertu","indication_name":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Enhertu","company_name":"Washington D.C. Veterans Affairs Medical Center","drug_phase":"marketed","molecular_target":"DNA topoisomerase 1, Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"gemcitabin","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gemcitabin","company_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","drug_phase":"marketed","molecular_target":"UMP-CMP kinase, Deoxycytidine kinase, Ribonucleoside-diphosphate reductase large subunit","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"gemcitabin","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gemcitabin","company_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","drug_phase":"marketed","molecular_target":"UMP-CMP kinase, Deoxycytidine kinase, Ribonucleoside-diphosphate reductase large subunit","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"cosibelimab","indication_name":"metastatic cutaneous squamous cell carcinoma (mCSCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unloxcyt","generic_name":"COSIBELIMAB","company_name":"Checkpoint Therapeutics Inc","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Unloxcyt blocks the PD-1/PD-L1 pathway to help the immune system recognize and attack cancer cells."},{"drug_id":"inbakicept","indication_name":"BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anktiva","generic_name":"INBAKICEPT","company_name":"Altor Bioscience, Llc, An Indirect Wholly-Owned Su","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":40,"revenue":null,"mechanism":"Anktiva works by targeting a specific target to treat BCG-unresponsive nonmuscle invasive bladder cancer."},{"drug_id":"nicotinamide","indication_name":"Niacin deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Infuvite Adult","generic_name":"Nicotinamide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"NAD-dependent protein deacetylase sirtuin-2","drug_class":"Standardized Chemical Allergen [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"avastin","indication_name":"Carcinoma of cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avastin","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"avastin","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avastin","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"avastin","indication_name":"Metastatic carcinoma to colon","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avastin","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"avastin","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avastin","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"technetium-99mtc-nofetumomab-merpentan","indication_name":"Nuclear medicine imaging procedure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Verluma","generic_name":"technetium (99mTc) nofetumomab merpentan","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"ixabepilone","indication_name":"Carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ixempra Kit","generic_name":"IXABEPILONE","company_name":"R-Pharm Us Llc","drug_phase":"marketed","molecular_target":"Apoptosis regulator Bcl-2","drug_class":"Microtubule Inhibitor","quality_score":64,"revenue":null,"mechanism":"Ixempra Kit works by disrupting cell division, preventing cancer cells from growing and multiplying."},{"drug_id":"ixabepilone","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ixempra Kit","generic_name":"IXABEPILONE","company_name":"R-Pharm Us Llc","drug_phase":"marketed","molecular_target":"Apoptosis regulator Bcl-2","drug_class":"Microtubule Inhibitor","quality_score":64,"revenue":null,"mechanism":"Ixempra Kit works by disrupting cell division, preventing cancer cells from growing and multiplying."},{"drug_id":"evocalcet","indication_name":"Hypercalcemia in parathyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orkedia","generic_name":"EVOCALCET","company_name":"Kyowa Hakko Kirin Co., Ltd.","drug_phase":"marketed","molecular_target":"Extracellular calcium-sensing receptor","drug_class":"","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"estradiol","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estrace","generic_name":"ESTRADIOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Estrace works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."},{"drug_id":"estradiol","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estrace","generic_name":"ESTRADIOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Estrace works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."},{"drug_id":"estradiol","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estrace","generic_name":"ESTRADIOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Estrace works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."},{"drug_id":"etoposide","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vepesid","generic_name":"etoposide","company_name":"Bristol-Myers Squibb K.K.","drug_phase":"marketed","molecular_target":"DNA topoisomerase 2-alpha","drug_class":"Topoisomerase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"oxaliplatin","indication_name":"Lymph Node Positive Colorectal Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eloxatin","generic_name":"Oxaliplatin","company_name":"Yakult Honsha","drug_phase":"marketed","molecular_target":"DNA","drug_class":"Platinum-based chemotherapy agent","quality_score":70,"revenue":null,"mechanism":"Oxaliplatin forms platinum-DNA crosslinks that inhibit replication and transcription."},{"drug_id":"gemcitabine-hydrochloride","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gemzar","generic_name":"Gemcitabine Hydrochloride","company_name":"Accord Hlthcare","drug_phase":"marketed","molecular_target":"Ribonucleotide reductase; DNA incorporation","drug_class":"Nucleoside metabolic inhibitor","quality_score":69,"revenue":null,"mechanism":"Gemcitabine kills cells during DNA synthesis and blocks G1/S-phase progression."},{"drug_id":"gemcitabine-hydrochloride","indication_name":"Metastatic Breast Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gemzar","generic_name":"Gemcitabine Hydrochloride","company_name":"Accord Hlthcare","drug_phase":"marketed","molecular_target":"Ribonucleotide reductase; DNA incorporation","drug_class":"Nucleoside metabolic inhibitor","quality_score":69,"revenue":null,"mechanism":"Gemcitabine kills cells during DNA synthesis and blocks G1/S-phase progression."},{"drug_id":"medroxyprogesterone","indication_name":"Endometrial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depo-Provera","generic_name":"medroxyprogesterone","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Progesterone receptor","drug_class":"Progestin","quality_score":null,"revenue":null,"mechanism":"Depo-Provera works by binding to the progesterone receptor in the body, which helps to regulate the menstrual cycle and prevent pregnancy."},{"drug_id":"bleomycin","indication_name":"International Federation of Gynecology and Obstetrics stage finding for vulvar carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Blenoxane","generic_name":"BLEOMYCIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Aspartyl/asparaginyl beta-hydroxylase","drug_class":"Cytoprotective Agent","quality_score":62,"revenue":null,"mechanism":"Bleomycin works by binding to DNA and causing strand breaks, which ultimately leads to cell death."},{"drug_id":"bleomycin","indication_name":"Squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Blenoxane","generic_name":"BLEOMYCIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Aspartyl/asparaginyl beta-hydroxylase","drug_class":"Cytoprotective Agent","quality_score":62,"revenue":null,"mechanism":"Bleomycin works by binding to DNA and causing strand breaks, which ultimately leads to cell death."},{"drug_id":"ampicillin","indication_name":"Skin and Skin Structure Acinetobacter Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"licensed-influenza-vaccine-3","indication_name":"Intranasal influenza vaccine for active immunization against influenza disease caused by influenza virus types A and B, in individuals 6 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Assorted Licensed Hand Sanitizer Grape 01","generic_name":"Licensed Influenza Vaccine 3","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Influenza virus hemagglutinin protein","drug_class":"Vaccine","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"goserelin","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zoladex","generic_name":"goserelin","company_name":"Tersera","drug_phase":"marketed","molecular_target":"pituitary gonadotropin secretion","drug_class":"Gonadotropin Releasing Hormone Receptor Agonist","quality_score":54,"revenue":null,"mechanism":"ZOLADEX inhibits pituitary gonadotropin secretion, leading to regression or inhibition of hormonally sensitive tumors."},{"drug_id":"goserelin-acetate","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zoladex","generic_name":"GOSERELIN ACETATE","company_name":"Tersera","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"Gonadotropin Releasing Hormone Receptor Agonist","quality_score":54,"revenue":null,"mechanism":"Zoladex works by mimicking the body's natural hormone to reduce testosterone production."}],"pipeline":[{"drug_id":"olaparib-oral-product","indication_name":"Advanced prostate adenocarcinoma with neuroendocrine differentiation","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib Oral Product","company_name":"Duke University","drug_phase":"discontinued","molecular_target":"PARP-1 and PARP-2 (poly-ADP-ribose polymerase enzymes)","drug_class":"PARP inhibitor (DNA repair inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits poly-ADP-ribose polymerase (PARP) enzymes to impair DNA repair in cancer cells with BRCA mutations or homologous recombination deficiency."},{"drug_id":"pf-06940434","indication_name":"Squamous Cell Carcinoma of the Head and Neck","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06940434","generic_name":"pf-06940434","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 2","quality_score":null,"revenue":null,"mechanism":"PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 2"},{"drug_id":"dacomitnib","indication_name":"Carcinoma, Non-Small-Cell Lung","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"dacomitnib","generic_name":"dacomitnib","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis","quality_score":null,"revenue":null,"mechanism":"patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis"},{"drug_id":"sasanlimab-prefilled-syringe","indication_name":"Carcinoma, Non-Small-Cell Lung","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sasanlimab Prefilled syringe","generic_name":"sasanlimab-prefilled-syringe","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"prefilled syringe","quality_score":0,"revenue":null,"mechanism":"prefilled syringe"},{"drug_id":"pd-0332991","indication_name":"Advanced Hepatocellular Carcinoma","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PD-0332991","generic_name":"pd-0332991","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase TAO2","drug_class":"PD-0332991, 125mg, 3 cycles","quality_score":null,"revenue":null,"mechanism":"PD-0332991, 125mg, 3 cycles"},{"drug_id":"nitroglycerin","indication_name":"Enhancing wound perfusion in high-risk lower extremity orthopaedic surgery","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NITROGLYCERIN","company_name":"","drug_phase":"marketed","molecular_target":"Nitric oxide synthase pathway","drug_class":"Nitrate Vasodilator [EPC]","quality_score":10,"revenue":null,"mechanism":"Nitroglycerin forms nitric oxide, which activates guanylate cyclase, leading to increased cyclic GMP and subsequent vasodilation in smooth muscle."},{"drug_id":"tyrosine-kinase-inhibitor-tki","indication_name":"Renal Cell Carcinoma (RCC)","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tyrosine kinase inhibitor (TKI)","generic_name":"tyrosine-kinase-inhibitor-tki","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"TKIs","quality_score":null,"revenue":null,"mechanism":"TKIs"},{"drug_id":"sea-tgt","indication_name":"Carcinoma, Non-Small-Cell Lung","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SEA-TGT","generic_name":"sea-tgt","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"solution in vials","quality_score":null,"revenue":null,"mechanism":"solution in vials"},{"drug_id":"rifampin","indication_name":"Rifampicin-resistant Tuberculosis","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RIFAMPIN","company_name":"","drug_phase":"marketed","molecular_target":"DNA-dependent RNA polymerase","drug_class":"Rifamycin Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Rifampin inhibits DNA-dependent RNA polymerase activity in susceptible Mycobacterium tuberculosis organisms."}],"offLabel":[],"totalMarketed":792,"totalPipeline":9},"trials":{"data":[{"nct_id":"NCT06199934","title":"Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":19853610,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04365114","title":"Patient Outcomes from Second Film-readers and Test Threshold Relaxation in Breast Screening","phase":"","overall_status":"COMPLETED","enrollment_count":13094122,"lead_sponsor_name":"University of Warwick","has_results":false},{"nct_id":"NCT06700941","title":"Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment","phase":"","overall_status":"COMPLETED","enrollment_count":8000000,"lead_sponsor_name":"Universidad Nacional de Colombia","has_results":false},{"nct_id":"NCT05126992","title":"EU Secondary Data Post-Authorisation Safety Study of AZD1222","phase":"","overall_status":"COMPLETED","enrollment_count":5321930,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04848441","title":"Risk of COVID-19 Infection After Vaccination","phase":"","overall_status":"UNKNOWN","enrollment_count":2000000,"lead_sponsor_name":"Umeå University","has_results":false},{"nct_id":"NCT05993260","title":"Using Text Messages to Boost COVID-19 Vaccine Booking Rate","phase":"NA","overall_status":"COMPLETED","enrollment_count":1825937,"lead_sponsor_name":"The Behavioural Insights Team","has_results":false},{"nct_id":"NCT01267851","title":"Clinical Database and Biobank of Patients With Gynecologic Neoplasms","phase":"","overall_status":"UNKNOWN","enrollment_count":1600000,"lead_sponsor_name":"Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT05234333","title":"COVID-19 Vaccines Associated Malaise","phase":"","overall_status":"COMPLETED","enrollment_count":1534706,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT05873751","title":"A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.","phase":"","overall_status":"COMPLETED","enrollment_count":1307378,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03776435","title":"CT Carcinogenic Risk in Patients With Appendicitis","phase":"","overall_status":"UNKNOWN","enrollment_count":1000000,"lead_sponsor_name":"Seoul National University Bundang Hospital","has_results":false},{"nct_id":"NCT04551248","title":"Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.","phase":"","overall_status":"UNKNOWN","enrollment_count":1000000,"lead_sponsor_name":"Sungkyunkwan University","has_results":false},{"nct_id":"NCT01077817","title":"Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)","phase":"","overall_status":"COMPLETED","enrollment_count":684815,"lead_sponsor_name":"Organon and Co","has_results":true},{"nct_id":"NCT07231016","title":"Influenza Vaccination Against Infectious Complications and Mortality in Older Adults With Fractures: a Large-scale Retrospective Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":561566,"lead_sponsor_name":"Taipei Medical University Hospital","has_results":false},{"nct_id":"NCT03943810","title":"Analysis and Improvising Working Practices in the ER","phase":"","overall_status":"COMPLETED","enrollment_count":500000,"lead_sponsor_name":"Sheba Medical Center","has_results":false},{"nct_id":"NCT07117045","title":"Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":400000,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT05186571","title":"Myopericarditis After Messenger Ribonucleic Acid (mRNA) COVID-19 Vaccination in Children 5-11 Years Old","phase":"","overall_status":"UNKNOWN","enrollment_count":350000,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT05027464","title":"Developing and Testing a COVID-19 Vaccination Acceptance Intervention","phase":"NA","overall_status":"COMPLETED","enrollment_count":338718,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT04579822","title":"Maternal and Fetal Outcomes Following Influenza Vaccination in Pregnancy","phase":"","overall_status":"UNKNOWN","enrollment_count":300000,"lead_sponsor_name":"Sungkyunkwan University","has_results":false},{"nct_id":"NCT04801524","title":"Text-based Reminders to Promote COVID-19 Vaccinations","phase":"NA","overall_status":"COMPLETED","enrollment_count":250000,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT06722040","title":"Effect and Safety of a Pediatric Triage Track on Hospital Visits and at the Public Medical Helpline 1813, Capital Region, Denmark","phase":"","overall_status":"COMPLETED","enrollment_count":244000,"lead_sponsor_name":"Emergency Medical Services, Capital Region, Denmark","has_results":false},{"nct_id":"NCT05537441","title":"Precision Vaccine Promotion in Underserved Populations","phase":"NA","overall_status":"COMPLETED","enrollment_count":228831,"lead_sponsor_name":"University of Southern California","has_results":true},{"nct_id":"NCT04800965","title":"Text-based Interventions to Promote COVID-19 Vaccinations","phase":"NA","overall_status":"COMPLETED","enrollment_count":200000,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT06678360","title":"Perioperative Impact of Physical Activity on Short- and Long-term Morbidity and Mortality","phase":"","overall_status":"RECRUITING","enrollment_count":180000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT05586178","title":"Information Provision and Consistency Framing to Increase COVID-19 Booster Uptake","phase":"NA","overall_status":"COMPLETED","enrollment_count":177720,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT03666026","title":"Patient Portal - Flu Reminder Recall","phase":"NA","overall_status":"COMPLETED","enrollment_count":164205,"lead_sponsor_name":"University of California, Los Angeles","has_results":true},{"nct_id":"NCT05586204","title":"Boost Intentions and Facilitate Action to Promote COVID-19 Booster Take-up","phase":"NA","overall_status":"COMPLETED","enrollment_count":154977,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT01696968","title":"Screening for Lung Cancer in Older Patients (PLCO Screening Trial)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":154901,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01696981","title":"Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":154900,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04910802","title":"Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":150000,"lead_sponsor_name":"Miriam Elfström","has_results":false},{"nct_id":"NCT06180447","title":"Peri-conceptional or Pregnancy Exposure of Vaccination and the Risk of Adverse Pregnancy Outcomes","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150000,"lead_sponsor_name":"Sun Xin","has_results":false},{"nct_id":"NCT06719193","title":"DeMONSTRATE-TB Study in Ethiopia","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":131438,"lead_sponsor_name":"Management Sciences for Health","has_results":false},{"nct_id":"NCT05499299","title":"Volatility and Heterogeneity of Vaccine Sentiments Means Continuous Monitoring is Needed When Measuring Message Effectiveness","phase":"NA","overall_status":"COMPLETED","enrollment_count":127000,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT04576962","title":"County Level Correlates of HPV Vaccine Series Completion Among Children Ages 11-14 Years in Indiana","phase":"","overall_status":"COMPLETED","enrollment_count":122152,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT04323137","title":"Encouraging Flu Vaccination Among High-Risk Patients Identified by ML","phase":"NA","overall_status":"COMPLETED","enrollment_count":117649,"lead_sponsor_name":"Geisinger Clinic","has_results":true},{"nct_id":"NCT05225064","title":"Increasing COVID-19 Vaccine Uptake in Developing Countries (Bihar)","phase":"NA","overall_status":"COMPLETED","enrollment_count":114512,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT06646406","title":"Evaluation of a Multilevel Intervention on Adult COVID-19 and Influenza Vaccination Rate","phase":"NA","overall_status":"COMPLETED","enrollment_count":114165,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06898775","title":"Passive Safety Surveillance Data of Dengue Vaccine, Qdenga (TAK 003) in Private Vaccination Sites in Buenos Aires, Argentina.","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":112345,"lead_sponsor_name":"Fundación Vacunar","has_results":false},{"nct_id":"NCT05586165","title":"Effects of Prompt to Bundle COVID-19 Booster and Flu Shot","phase":"NA","overall_status":"COMPLETED","enrollment_count":109493,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT05766189","title":"Wastewater Surveillance to Boost COVID-19 Vaccine Uptake","phase":"NA","overall_status":"COMPLETED","enrollment_count":100000,"lead_sponsor_name":"Syracuse University","has_results":false},{"nct_id":"NCT02620852","title":"Women Informed to Screen Depending on Measures of Risk (Wisdom Study)","phase":"NA","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT02924467","title":"Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates in New York State","phase":"NA","overall_status":"COMPLETED","enrollment_count":100000,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT05095844","title":"National Vaccine Adverse Event Reporting Survey and Etiology","phase":"","overall_status":"UNKNOWN","enrollment_count":100000,"lead_sponsor_name":"Neuroganics LLC","has_results":false},{"nct_id":"NCT05013944","title":"AnovaOS Network Powered Patient Registry","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Anova Enterprises, Inc","has_results":false},{"nct_id":"NCT07372950","title":"Kaiser Colorado Flu Nudge","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Kaiser Permanente","has_results":false},{"nct_id":"NCT05368038","title":"ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100000,"lead_sponsor_name":"Albert Einstein College of Medicine","has_results":false},{"nct_id":"NCT06831383","title":"The STOP-HPV Scale Up Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT07317726","title":"Recent Trends in Stage Migration of Gastrointestnial Carcinoid Tumors Over Two Decades: a Retrospective SEER-based Analysis 2000-2022","phase":"","overall_status":"COMPLETED","enrollment_count":93481,"lead_sponsor_name":"Suez Canal University","has_results":false},{"nct_id":"NCT07317713","title":"A Two-decade Mortality Risk Analysis of Gastrointestinal Carcinoid Neoplasms: an Updated SEER-based Study 2000-2022","phase":"","overall_status":"COMPLETED","enrollment_count":93481,"lead_sponsor_name":"Suez Canal University","has_results":false},{"nct_id":"NCT07291752","title":"The Risk of Second Primary Gastrointestinal Malignancies Following Primary Gastrointestinal Carcinoid Tumors: a SEER Based Study 2000-2022","phase":"","overall_status":"COMPLETED","enrollment_count":93481,"lead_sponsor_name":"Suez Canal University","has_results":false},{"nct_id":"NCT06938139","title":"Defining Benchmarks for Gastric Cancer Patients Underwent Minimal Invasive Gastrectomy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":90000,"lead_sponsor_name":"Fujian Medical University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}